BR112018009753B1 - Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana - Google Patents

Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana Download PDF

Info

Publication number
BR112018009753B1
BR112018009753B1 BR112018009753-5A BR112018009753A BR112018009753B1 BR 112018009753 B1 BR112018009753 B1 BR 112018009753B1 BR 112018009753 A BR112018009753 A BR 112018009753A BR 112018009753 B1 BR112018009753 B1 BR 112018009753B1
Authority
BR
Brazil
Prior art keywords
proteins
bacterial strain
protein
virulence
negative bacterial
Prior art date
Application number
BR112018009753-5A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112018009753A2 (pt
BR112018009753A8 (pt
Inventor
Simon Ittig
Marlise Amstutz
Christoph Kasper
Guy R. Cornelis
Original Assignee
Universität Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Basel filed Critical Universität Basel
Priority to BR122023024697-7A priority Critical patent/BR122023024697A2/pt
Publication of BR112018009753A2 publication Critical patent/BR112018009753A2/pt
Publication of BR112018009753A8 publication Critical patent/BR112018009753A8/pt
Publication of BR112018009753B1 publication Critical patent/BR112018009753B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112018009753-5A 2015-11-19 2016-11-17 Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana BR112018009753B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122023024697-7A BR122023024697A2 (pt) 2015-11-19 2016-11-17 Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15195490.6 2015-11-19
EP15195490 2015-11-19
PCT/EP2016/078084 WO2017085233A1 (en) 2015-11-19 2016-11-17 Virulence attenuated bacteria for treatment of malignant solid tumors

Publications (3)

Publication Number Publication Date
BR112018009753A2 BR112018009753A2 (pt) 2018-11-13
BR112018009753A8 BR112018009753A8 (pt) 2019-02-26
BR112018009753B1 true BR112018009753B1 (pt) 2024-02-20

Family

ID=54697464

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018009753-5A BR112018009753B1 (pt) 2015-11-19 2016-11-17 Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana
BR122023024697-7A BR122023024697A2 (pt) 2015-11-19 2016-11-17 Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122023024697-7A BR122023024697A2 (pt) 2015-11-19 2016-11-17 Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana

Country Status (24)

Country Link
US (1) US11166987B2 (enExample)
EP (2) EP3377094B1 (enExample)
JP (1) JP7060503B2 (enExample)
KR (1) KR102736981B1 (enExample)
CN (1) CN108472348B (enExample)
AU (1) AU2016358257B2 (enExample)
BR (2) BR112018009753B1 (enExample)
CA (1) CA3003563A1 (enExample)
CY (1) CY1124564T1 (enExample)
DK (1) DK3377094T3 (enExample)
EA (1) EA201890868A1 (enExample)
ES (1) ES2880431T3 (enExample)
HR (1) HRP20211191T1 (enExample)
HU (1) HUE055132T2 (enExample)
IL (1) IL259052B2 (enExample)
LT (1) LT3377094T (enExample)
PL (1) PL3377094T3 (enExample)
PT (1) PT3377094T (enExample)
RS (1) RS62152B1 (enExample)
SG (1) SG11201803643TA (enExample)
SI (1) SI3377094T1 (enExample)
SM (1) SMT202100423T1 (enExample)
WO (1) WO2017085233A1 (enExample)
ZA (1) ZA201803902B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001431B (zh) 2014-05-21 2022-11-01 巴塞尔大学 基于细菌的蛋白质递送
SMT202000620T1 (it) 2015-11-19 2021-01-05 Univ Basel Distribuzione di proteine basata su batteri
JP6976351B2 (ja) 2016-12-20 2021-12-08 ウニヴェルズィテート・バーゼルUniversitat Basel 弱毒化細菌に基づくタンパク質送達
KR102110993B1 (ko) * 2018-12-20 2020-05-14 한국생명공학연구원 클레브시엘라 아에로제네스(Klebsiella aerogenes) 균주를 유효성분으로 포함하는 암 진단, 예방 또는 치료용 조성물
IL302334A (en) * 2020-10-27 2023-06-01 T3 Pharmaceuticals Ag Providing bacteria-based protein
CN114712496B (zh) * 2022-04-29 2023-10-13 中山大学·深圳 一种展示新抗原的细菌衍生外膜囊泡疫苗及制备方法和在制备癌症免疫治疗试剂盒中的应用
CN116064877B (zh) * 2023-02-09 2024-09-20 宁夏大学 利用lamp技术快速检测阴沟肠杆菌的试剂盒及方法
CN116855496B (zh) * 2023-07-05 2024-08-16 郑州大学 含有干扰序列siRNA-HIF-1α的表达质粒在制备抗肝细胞癌药物中的应用
EP4761753A2 (en) * 2023-08-17 2026-06-24 Baccine Ltd. Genetically modified bacteria for multi-modal secretion of a neoantigen

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
US6596509B1 (en) 1998-07-10 2003-07-22 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type III secretion systems
US20020160502A1 (en) 2000-09-26 2002-10-31 Roger Williams Hospital Recombinant BCG vaccines for the prevention and treatment of cancer
AU2002312778A1 (en) 2001-03-26 2002-10-08 Universite Catholique De Louvain Type iii bacterial strains for use in medicine
US8058442B2 (en) 2002-11-07 2011-11-15 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
FR2862312B1 (fr) 2003-11-13 2006-02-17 Univ Grenoble 1 Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas
US8357373B2 (en) 2005-10-04 2013-01-22 Ludwig Institute For Cancer Research Methods for stimulating an immune response using bacterial antigen delivery system
WO2008019183A2 (en) 2006-05-18 2008-02-14 The Regents Of The University Of California Biopolymer and protein production using type iii secretion systems of gram negative bacteria
TW200819540A (en) * 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EP2268313A2 (en) 2008-03-17 2011-01-05 Universitätsklinikum Münster Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
EP2717886B1 (en) 2011-06-08 2021-09-01 Chelation Partners Incorporated Metal chelating compositions and methods for controlling the growth or activities of a living cell or organism
US9127284B2 (en) * 2012-05-04 2015-09-08 The University Of Hong Kong Modified bacteria and their uses thereof for the treatment of cancer or tumor
JP6936934B2 (ja) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−4受容体結合融合タンパク質及びその使用
US10143743B2 (en) 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
CN107001431B (zh) 2014-05-21 2022-11-01 巴塞尔大学 基于细菌的蛋白质递送
SMT202000620T1 (it) 2015-11-19 2021-01-05 Univ Basel Distribuzione di proteine basata su batteri
JP6976351B2 (ja) 2016-12-20 2021-12-08 ウニヴェルズィテート・バーゼルUniversitat Basel 弱毒化細菌に基づくタンパク質送達

Also Published As

Publication number Publication date
IL259052A (en) 2018-07-31
JP7060503B2 (ja) 2022-04-26
CA3003563A1 (en) 2017-05-26
US20190015497A1 (en) 2019-01-17
EP3377094A1 (en) 2018-09-26
HRP20211191T1 (hr) 2021-10-29
ZA201803902B (en) 2019-03-27
CN108472348A (zh) 2018-08-31
KR102736981B1 (ko) 2024-12-02
JP2019500026A (ja) 2019-01-10
IL259052B2 (en) 2024-03-01
BR122023024697A2 (pt) 2023-12-26
BR112018009753A2 (pt) 2018-11-13
IL259052B1 (en) 2023-11-01
SMT202100423T1 (it) 2021-09-14
US11166987B2 (en) 2021-11-09
CN108472348B (zh) 2022-12-27
HUE055132T2 (hu) 2021-11-29
AU2016358257A1 (en) 2018-05-10
ES2880431T3 (es) 2021-11-24
BR112018009753A8 (pt) 2019-02-26
AU2016358257B2 (en) 2023-08-17
LT3377094T (lt) 2021-08-10
PT3377094T (pt) 2021-07-08
EP3377094B1 (en) 2021-04-28
RS62152B1 (sr) 2021-08-31
HK1256137A1 (en) 2019-09-13
DK3377094T3 (da) 2021-08-02
EA201890868A1 (ru) 2018-12-28
PL3377094T3 (pl) 2021-12-13
SI3377094T1 (sl) 2021-09-30
WO2017085233A1 (en) 2017-05-26
EP3903813A1 (en) 2021-11-03
SG11201803643TA (en) 2018-06-28
KR20180081583A (ko) 2018-07-16
CY1124564T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
ES2880431T3 (es) Bacterias de virulencia atenuada para el tratamiento de tumores sólidos malignos
US20240401065A1 (en) Bacteria-Based Protein Delivery
US11702663B2 (en) Bacteria-based protein delivery
US12516089B2 (en) Bacteria based protein delivery
EA040558B1 (ru) Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей
HK1256137B (en) Virulence attenuated bacteria for treatment of malignant solid tumors
CA3005380C (en) Bacteria-based protein delivery
BR112018009782B1 (pt) Cepas bacterianas recombinantes gram-negativas transformadas com um vetor e vetores
HK1256138B (en) Bacteria-based protein delivery

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 39/00 , A61K 39/02

Ipc: C12N 1/21 (2006.01), A61K 39/02 (2006.01), A61K 39

B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023024697-7 PROTOCOLO 870230103732 EM 24/11/2023 17:52.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/11/2016, OBSERVADAS AS CONDICOES LEGAIS